oronary artery disease (CAD) is the most common cause of left ventricular dysfunction and heart failure (ischemic cardiomyopathy [ICM]). The increasing sophistication of coronary artery bypass grafting (CABG) and percutaneous intervention (PCI) raises important questions about the appropriate role of revascularization, CABG, or PCI in treating patients with ICM. Understandings now in hand provide guidance regarding clinical decision making, underscore areas of uncertainty, and point to next steps in the quest to better understand the role of revascularization in these patients.
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CABG VERSUS OPTIMAL MEDICAL THERAPY FOR THE TREATMENT OF PATIENTS WITH ICM
The STICHES (Surgical Treatment for Ischemic Heart Failure Extension Study) 1 examined long-term outcomes in patients with left ventricular ejection fraction ≤35%, CAD without left main coronary artery stenosis ≥50%, New York Heart Association Functional Class 2 or 3 heart failure, and Canadian Cardiovascular Society Angina Class ≤2 randomized to Optimal Medical Therapy (OMT) or to OMT and CABG. A primary outcome event (death from any cause) occurred in 58.9% of patients with CABG plus OMT and 66.1% of patients randomized to OMT only (hazard ratio for CABG versus OMT, 0.84; 95% CI, 0.73-0.97; P=0.02).
These data provide high-quality evidence that revascularization with CABG improves outcomes in patients with ICM with suitable anatomy. It is important to note that the benefit was present in the group as a whole despite the early risk accompanying surgery.
SELECTING PATIENTS WITH ICM LIKELY TO BENEFIT FROM CABG
Patients with ICM frequently have comorbidities that increase surgical risk. Decisions regarding CABG require weighing the potential long-term survival advantage of CABG against the near-term risk of death or permanent disability.
Can we use imaging to predict which patients will benefit from CABG? Despite promising uncontrolled data, viability assessment using single-photon emission tomography failed to predict which STICH patients would benefit from revascularization. 2 Both US and European guidelines recognize that no diagnostic modality has been proven to predict survival benefit.
Kim et al 3 showed that hyperenhancement extent on MRI predicts the return of segmental function. Whether MRI can be refined to predict clinical outcome remains to be determined. Also, given prior data, it would be premature to abandon studying either single-photon emission tomography or positron emission tomography as predictors of possible benefit from CABG.
Nonetheless, the possibility also exists that there is benefit from revascularization that cannot be accurately predicted by imaging.
IS THERE A ROLE FOR PCI IN ICM?
There are no randomized trials of CABG versus PCI in the treatment of ICM. However, a recent meta-analysis by Wolff There are potential reasons that CABG may be superior to PCI. 5 Arteries with atherosclerosis have diffuse disease, including areas not severely narrowed. All of the atherosclerotic regions, including those with nonobstructive disease, are at risk for a thrombotic event as can be seen in data showing that myocardial infarctions in patients with known CAD frequently occur at a site different from that of the most severe stenosis on prior arteriography. The point is that there is a finite probability of an ischemic event being caused by the disease at each point in the artery, the probability of a clinical event being related to the sum of the probabilities at each point along the artery. CABG may mitigate the risk of an ischemic event in a larger segment of the artery compared with PCI, which treats a lesser extent of the artery. If this reasoning is true, then it is unlikely that new stent platforms will alter the relative effectiveness of CABG versus PCI.
Not infrequently, patients with ICM have comorbidities, such as renal insufficiency or frailty, which makes their surgical risk too high to proceed. Among patients at prohibitive risk for CABG because of comorbidities but whose arteries are amenable to PCI, the question is whether to perform PCI or treat with OMT alone. The Wolff meta-analysis suggests that PCI is superior to OMT, but only a randomized trial can offer a definitive answer.
CONCLUSIONS AND NEXT STEPS
1. CABG in addition to OMT is superior to OMT alone in the treatment of patients with ICM with acceptable surgical risk.
2. For patients with high surgical risk but in whom PCI is feasible, the question is whether to add PCI to OMT. A randomized clinical trial is needed to definitively assess the role of PCI in patients with ICM, particularly those with excessive risk for CABG. Inclusion criteria will need careful thought. Most patients with ICM have complex disease, and diabetes mellitus is common. Previous clinical trials in patients with diabetes mellitus or high CAD complexity (high SYNTAX scores) have shown superiority of CABG over PCI, albeit in cohorts without many patients with low ejection fraction. 3. Of central importance is research assessing the role of imaging in predicting revascularization benefit as a basis for individualizing treatment decisions.
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